Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9700-0.1600 (-7.51%)
At close: 04:00PM EDT
Advertisement
Sign in to post a message.
  • G
    G
    This company is weak on so many levels. They don't have enough cash to pay for the expensive studies, and their bloated salaries and bonuses. Next stop $1. And that's being generous.
    Bearish
  • M
    MarketWatch
    If we can pull ourselves back above $3 slowly, things could get interesting.

    👉 Alzheimer's patent
    👉 Alzheimer's NIH grant
    👉 Alzheimer's Phase 2 trials commencement
    👉Wits partnership, Cancer related news
    👉 NPC enrollment

    👆 All could be pending PRs.
    Bullish
  • H
    H
    Next stop 1.50$. You can do it!
  • l
    linda
    Come on, we need a nuclear news to shot the price up
  • G
    G
    Before anyone will take this company seriously:
    - The nepotism must end. Scott Fine needs to find a replacement CFO for his son Josh Fine.
    - They all have to stop taking bonuses while shareholders are down more than 60% - absolutely repugnant.
    - Scott needs to stop diluting the shares every chance he gets, i.e. stealing from his loyal shareholders. To stop or at least slow the thievery, they'll have to get a large grant to go forward with the studies.
    - Scott needs to stop granting shares that he stole from the shareholders to members of the board and other colleagues.
    - The cyclodextrin business needs to start turning a profit.
    - They need to actually do the work of setting up and conducting the trials. After all, what are shareholders paying for?
    - Scott has to take responsibility for the share price being down 97% since he took the CEO position and reduce his salary by 60% until the stock price rises about $10 (which realistically could be never).

    Until this happens, most reasonable people won't invest in this company and the stock price will continue to drop.
    Bearish
  • l
    linda
    Hello, anyone here?
  • d
    domenico
    This company has to be sold ,.Next year the would have to sell more share to raise money to continue in business ..they can not sell shares for two [2 ] dollars .they have two good product in phase two .,.it would be a shame if the company dilute or go out of business . The only solution is to sell the company .I hope management is able to see the road ahead .
  • M
    MarketWatch
    This company has the Triple Negative Breast Cancer cure, IMO.

    https://www.reddit.com/r/CYTH/comments/tnoow7/triple_negative_breast_cancer_treatment/
    Bullish
  • l
    linda
    Can some big bp buy this company out with $55 per share?
  • S
    Shlomo
    if the Alzheimer drug continue to show positive data in bigger trials then this could move even higher than SAVA because of its very low valuation of 40 million .
    "The company announced its first annual report with the FDA related to the program in June 2019. The one-year report described a favorable safety profile as well as encouraging initial observations on potential benefit.

    "The report suggests cognitive and neurologic stability, indicating possible benefit," said Sharon Hrynkow PhD, CTDH's Chief Scientific Officer and Senior Vice President for Medical Affairs.

    Commenting on the report, N. Scott Fine, CTDH's Chairman and CEO, added, "The data suggest a positive safety profile in this patient, overall stabilization of disease, and improvement in certain behavioral aspects of the disease."

    Given that persons with late-onset Alzheimer's Disease are generally expected to decline during a one-year timeframe, the results with this patient are extremely promising.

    Based on data from this case, the company's Scientific Advisory Board formally endorsed plans to move forward with the launch of a clinical trial in Alzheimer's.

    Alzheimer's is Currently the Most Common Form of Dementia

    According to the Alzheimer's Association, 5.8 million Americans are living with Alzheimer's Disease. By 2050, this number is projected to rise to nearly 14 million.

    It's estimated that Alzheimer's and other dementias cost the US $290 billion annually. These costs could rise as high as $1.1 trillion by 2050."
    https://www.bioflorida.com/news/475664/Cyclo-Therapeutics-Prepares-for-Alzheimers-Development-Program-After-Success-with-First-Patient.htm
    Bullish
  • B
    Boy
    27 Days left to the end of the month

    By the end of the month, we are 3 or 4 of the following:

    Phase 1/2 results
    Open label study results
    EMA approval
    Alzheimer’s phase 2 FDA meeting/application
    Annual 10k filling (With tons of updates on various ongoing trails)

    Goodluck and cheers guys!
    Bullish
  • D
    Duke
    The CEO Scott Fine has already taken 3 companies to bankruptcy (CEDC, Better Place and Pacific Drilling). He's currently working on his 4th: Cyclo Therapeutics... while he and his son collect fat paychecks and bonuses.

    Members of the board of Forward Industries were extremely worried about the involvement of Scott Fine in their company:

    "Two of Mr. Wise's Nominees Oversaw the Destruction of Shareholder Value at Other Public Companies

    N. Scott Fine, one of Mr. Wise's nominees, served as a director of Central European Distribution Corporation (CEDC) for more than a decade prior to its Chapter 11 bankruptcy in 2013. Mr. Fine was Vice Chairman and Lead Director of the Board of CEDC at the time of the bankruptcy and it appears he was also Chairman of each of the Special Committee, Restructuring Committee and Audit Committee of the Board at the time of filing.

    ***The bankruptcy resulted in a complete destruction of value to all the equity holders. Nevertheless, Mr. Fine stayed on the Board of the newly reorganized successor entity and in connection with the bankruptcy received an incentive bonus of a stunning $1 million in cash from the new successor entity."***

    https://www.globenewswire.com/news-release/2014/12/16/1147039/0/en/Forward-Industries-Encourages-Shareholders-to-Review-Lack-of-Relevant-Qualifications-and-Experience-of-Dissident-Nominees-Offered-by-Terence-Bernard-Wise.html
    WEST PALM BEACH, FL--(Marketwired - Dec 15, 2014) - Reviews glaring public company failures overseen by N. Scott Fine and...
    WEST PALM BEACH, FL--(Marketwired - Dec 15, 2014) - Reviews glaring public company failures overseen by N. Scott Fine and...
    www.globenewswire.com
    Bearish
  • S
    Shlomo
    (CYTH-DD) Market Cap unbelievable 22 million / Cash $13 million / Shares Out 4.5 million / Potential BEST in Class Orphan Drug for the treatment of Nieman-Pick Disease (Phase 3) and they expect to Start Phase 2 for Alzheimer trial shortly = BRUTALLY Underpriced low float Biotech with HUGE upside Potential which could run to $50 and much higher on positive news .STRONG BUY

    NEW Presentation
    https://content.equisolve.net/cyclotherapeutics/media/b299bb06bee5ad13b2523b8c8754fb2d.pdf

    Summary
    https://assets.wallstreet-online.de/_media/8763/board/20210113142857-screenshot-2021-01-13-b299bb06bee5ad13b2523b8c875.png
    Bullish
  • D
    Dave
    Hoping for some big update regarding Fast FDA approval...can open by triple x if we will have....donot surprise...
    Bullish
  • E
    E.E
    Donald.......thanks for the insights. I quickly glanced at this stock. Don't know much about its Management. But, for NPC, The positive results for drug safety & efficacy from a rare disease, NPC clinical trials look promising....Assuming positive results continue, when Cyclo Therapeutics (C.T) receives FDA approval for its NPC treatment, it expects to generate $75 Million or in revenue in the US in 2022 or about $3.00 PPS & factored in subsequent years revenue accordingly. .........For Alzheimer treatment, there are a few competitors occupied in this space.  There is currently no cure for Alzheimer disease, after more than 30 years of research.... Many clinical trials have conducted.  There are currently about 6 million Americans suffer from Alzheimer. The annual treatment for Alzheimer & dementia is about $300 Billion.  This is huge (more than lung cancer of $18 Billion or diabetes $60 Billion market).......Since C.T received FDA fast track designation & this is Alzheimer market & small Market Cap, the reward is tremendous and outweighs the risk.  I like the diversity drug pipelines of Genprex much more.  But, I plan to invest long-term on C.T next week. especially at less than $0.25.  Can you shed lights on the 5 Management/employees? Also, look at CYDY when you have a chance. They just discovered that Its current HIV drug Leronlimab shows promises in treatment of mild to moderate COVID-19 cases on 4 patients so far. The FDA recommended they file 2nd protocol next week due to its urgency of COVID-19 cases.
  • S
    Shlomo
    We have a potential BEST in Class Orphan Drug in Phase 3 and a Alzheimer Program which shows promising data to date .And this Company is still valued at unbelievable 37 million we will have a lot of fun with this low float sleeping giant .GL
    Bullish
  • r
    rickrossy
    Going to hit $10 next week with the announcement of research developments. Do not sell yet. I’m adding another 1000 shares. Holding 4000 at the moment. I am confident of the announcements coming up.
    Bullish
  • R
    Ron
    $50 stock - risk-adjusted on NP alone. Tell me where I am wrong.
    Trying to back in to a potential market cap estimate.

    $550,000,000 addressable market (investor slide)
    30% market share (guess)
    90% Margin (investor slide)
    $148,500,000 EBITDA
    15% chance of success (phase II to launch statistics)
    $22,275,000 risk-adjusted EBITDA
    10x EBITDA multiple (very low guess and easy math)
    $222,275,000 risk-adjusted market cap
    4,570,000 shares outstanding
    $48.74 stock price
Advertisement
Advertisement